 - Previous participation in a clinical trial for either eye involving antiangiogenic drugs pegaptanib, rhuFab V2, anecortave acetate, protein kinase C inhibitors, etc. Previous intravitreal drug delivery e.g., intravitreal corticosteroid injection or device implantation in the study eye 